medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2022, Número 1

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (1)


Disfunción crónica de órganos en pacientes con drepanocitosis. Parte I: manifestaciones cardiorrespiratorias

Fernández ÁJD, Fernández GCT, de la Cruz AL

Idioma: Español
Referencias bibliográficas: 89
Paginas: 1-23
Archivo PDF: 471.44 Kb.


RESUMEN

Introducción: En la actualidad la mayoría de los pacientes con anemia falciforme alcanzan la adultez. La disfunción crónica de órganos constituye la causa primaria de muerte y representa un desafío en el manejo de estos enfermos.
Objetivo: Analizar los aspectos generales de la disfunción orgánica crónica en pacientes con drepanocitosis y profundizar en las alteraciones cardiorrespiratorias.
Métodos: Se realizó una revisión de los artículos publicados en los últimos diez años con el uso de los buscadores PubMed, SciELO y Google Académico. Los términos de búsqueda fueron: anemia de células falciformes, disfunción orgánica, mortalidad, hipertensión pulmonar, enfermedad pulmonar crónica, asma, apnea obstructiva del sueño.
Análisis y síntesis de la información: Con el aumento de la expectativa de vida, en el manejo de los pacientes con drepanocitosis, gana en relevancia el diagnóstico precoz y el tratamiento oportuno de la disfunción crónica de órganos. Este es un proceso que comienza en la infancia, pero se hace más evidente en la etapa adulta. Las manifestaciones cardiorrespiratorias más comunes y con impacto en la morbilidad y en la mortalidad son: la hipertensión pulmonar y la enfermedad pulmonar crónica. Se describen aspectos relacionado con la prevalencia, diagnóstico, implicaciones en la evolución de los enfermos y aspectos relacionados con su tratamiento.
Conclusiones: La hipertensión pulmonar y la enfermedad pulmonar crónica son frecuentes en pacientes con drepanocitosis. Ambas complicaciones tienen un impacto negativo en la evolución de estos enfermos y se asocian a aumento de la mortalidad. La detección temprana de estas afecciones, permite tomar acciones terapéuticas para disminuir sus consecuencias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Paulukonis ST, Eckman JR, Snyder AB, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep. Mar-Apr 2016;131(2):367-75. DOI: https://10.1177/003335491613100221

  2. Shet AS, Thein SL. A growing population of older adults with sickle cell disease. Clin Geriatr Med. 2019 Aug;35(3):349-67. DOI: https://10.1016/j.cger.2019.03.006

  3. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405. DOI: https://10.1016/j.amepre.2011.09.013

  4. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. Mar-Apr 2013;128(2):110-6. DOI: https://10.1177/003335491312800206

  5. DeBaun MR, Ghafuri DL, Rodeghier M, Maitra P, Chaturvedi S, Kassim A, et al. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis Blood. 2019 Feb 7;133(6):615-17. DOI: https://10.1182/blood-2018-10-880575

  6. Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years. Am J Hematol. 2016 Jan;91(1):5-14. DOI: https://10.1002/ajh.24235

  7. Vichinsky E. Chronic organ failure in adult sickle cell disease. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):435-39. DOI: https://10.1182/asheducation-2017.1.435

  8. Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica. 2017 Apr;102(4):626-636 DOI: https://10.3324/haematol.2016.153791

  9. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J, et al; Investigators of the Cooperative Study of Sickle Cell Disease. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003 Oct;123(2):359-65. DOI: https://10.1046/j.1365-2141.2003.04594.x

  10. Chaturvedi S, Ghafuri DL, Jordan N, Kassim A, Rodeghier M, DeBaun MR. Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study. Am J Hematol. 2018 Sep;93(9):1153-60. DOI: https://10.1002/ajh.25202

  11. Thein SL, Howard J. How I treat the older adult with sickle cell disease. Blood. 2018 Oct 25;132(17):1750-60. DOI: https://10.1182/blood-2018-03-818161

  12. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005 Nov;84(6):363-76. DOI: https://10.1097/01.md.0000189089.45003.53

  13. Chaturvedi S, Ghafuri DL, Kassim A, Rodeghier M, DeBaun MR. Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease. Am J Hematol. 2017 Feb;92(2):125-30. DOI: https://10.1002/ajh.24598

  14. vanTuijn CFJ, Schimme M, van Beers EJ, Nur E, Biemond BJ. Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study. Am J Hematol. 2017 Oct;92(10):E584-90. DOI: https://10.1002/ajh.24855

  15. Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med. 2013;64:451-66 DOI: https://10.1146/annurev-med-120611-143127

  16. Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L314-24 DOI: https://10.1152/ajplung.00252.2014

  17. Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, Citero VA, et al. Daily home opioid use in adults with sickle cell disease: the PiSCES project.J Opioid Manag. May-Jun 2015;11(3):243-53. DOI: https://10.5055/jom.2015.0273

  18. Kassim AA, Pruthi S, Day M, Rodeghier M, Gindville MC, Brodsky MA, et al. Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016 Apr 21;127(16):2038-40. DOI: https://10.1182/blood-2016-01-694562

  19. Amissah-Arthur KN, Mensah E. The past, present and future management of sickle cell retinopathy within an African context. Eye (Lond).2018 Aug;32(8):1304-14 DOI: https://10.1038/s41433-018-0162-8

  20. Rezende Ribeiro MVM, Omena Jucá JV, dos Santos Alves ALC, Oliveira Ferreira CV,Barbosa FT, Nogueira Ribeiro EA. Sickle cell retinopathy: A literature review. Rev Assoc Med Bras (1992). 2017 Dec;63(12):1100-3. DOI: https://10.1590/1806-9282.63.12.1100

  21. Stuart A, Smith MR. The emergence and prevalence of hearing loss in children with homozygous sickle cell disease. Int J Pediatr Otorhinolaryngol. 2019 Aug;123:69-74. DOI: https://10.1016/j.ijporl.2019.04.032

  22. Onakoya PA, Nwaorgu OGB, Shokunbi WA. Sensorineural hearing loss in adults with sickle cell anaemia. Afr J Med Med Sci 2002 Mar; 31(1):21-4.

  23. Mushemi-Blake S, Melikian N, Drasar E, Bhan A, Lunt A, Desai SR, et al. Pulmonary haemodynamics in sickle cell disease are driven predominantly by a highoutput state rather than elevated pulmonary vascular resistance: a prospective 3-dimensional echocardiography/Doppler study. PLoS One. 2015 Aug 13;10(8):e0135472. DOI: 10.1371/journal.pone.0135472

  24. Mathew R, Huang J, Wu JM, Fallon JT, Gewitz MH. Hematological disorders and pulmonary hypertension. World J Cardiol. 2016 Dec 26;8(12):703-18. DOI: https://10.4330/wjc.v8.i12.703

  25. Mehari A, Klings ES. Chronic pulmonary complications of sickle cell disease. Chest. 2016 May;149(5):1313-24 DOI: https://10.1016/j.chest.2015.11.016

  26. Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1264-9. DOI: https://10.1164/rccm.200601-125OC

  27. Khan AB, Kesse-Adu R, Breen C, Murphy PB, Chambers J, Holmes P, et al. A descriptive study of the characteristics of older adults with sickle cell disease. Am J Hematol. 2018 Feb;93(2):E38-E40. DOI: https://10.1002/ajh.24961

  28. Vazquez B, Shah B, Zhang X, Lash JP, Gordeuk VR, SarafSL,et al. Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. Am J Hematol. 2014 Dec;89(12):1156-7 DOI: https://10.1002/ajh.23817

  29. Sharpe CC, Thein SL. How I treat renal complications in sickle cell disease. Blood. 2014 Jun 12;123(24):3720-6 DOI: https://10.1182/blood-2014-02-557439

  30. Shah R, Taborda C, Chawla S. Acute and chronic hepatobiliary manifestations of sickle cell disease: A review. World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):108-16. DOI: https://10.4291/wjgp.v8.i3.108

  31. Adesina OO, Neumayr LD. Osteonecrosis in sickle cell disease: an update of risk factors, diagnosis, and management. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):351-8. DOI: https://10.1182/hematology.2019000038

  32. Monfort JB, Senet P. Leg ulcers in sickle-cell disease: treatment update. Adv Wound Care (New Rochelle). 2020 Jun;9(6):348-56. DOI: https://10.1089/wound.2018.0918

  33. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50 DOI: https://10.1016/j.jacc.2013.10.032

  34. Maron BA, Brittain EL, Choudhary G, Gladwin MT. Redefining pulmonary hypertension. Lancet Respir Med. 2018 Mar;6(3):168-70. DOI: https://10.1016/S2213-2600(17)30498-8

  35. Maron BA, Wertheim BM, Gladwin MT. Under pressure to clarify pulmonary hypertension clinical risk. Am J Respir Crit Care Med. 2018 Feb 15;197(4):423-6. DOI: https://10.1164/rccm.201711-2306ED

  36. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913 DOI: https://10.1183/13993003.01913-2018

  37. Amadi VN, Balogun MO, Akinola NO, Adebayo RA, Akintomide AO. Pulmonary hypertension in nigerian adults with sickle cell anemia. Vasc Health Risk Manag. 2017 May 8;13:153-160. DOI: https://10.2147/VHRM.S92799/

  38. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 Dec;34(6):1219-63. DOI: https://10.1183/09031936.00139009

  39. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. DOI: https://10.1016/j.jacc.2004.02.037

  40. Simonneau G, Gatzoulis MA, Adatia I. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. DOI: https://10.1016/j.jacc.2013.10.029

  41. Schreier DA, Forouzan O, Hacker TA, Sheehan J, Chesler N. Increased red blood cell stiffness increases pulmonary vascular resistance and pulmonary arterial pressure. J Biomech Eng. 2016 Feb;138(2):021012. DOI: https://10.1115/1.4032187

  42. Mehari A, Alam S, Tian X, Cuttica MJ, Barnett CF, Miles G, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med. 2013 Apr 15;187(8):840-7. DOI: https://10.1164/rccm.201207-1222OC

  43. Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, et al. American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. DOI: https://10.1164/rccm.201401-0065ST

  44. Mehari A, Igbineweka N, Allen D, Nichols J, Thein SL, Weir NA. Abnormal ventilation-perfusion scan is associated with pulmonary hypertension in sickle cell adults. J Nucl Med. 2019 Jan;60(1):86-92. DOI: https://10.2967/jnumed.118.211466

  45. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Feb 26;350(9):886-95 DOI: https://10.1056/NEJMoa035477

  46. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006 Jul;134(1):109-15 DOI: https://10.1111/j.1365-2141.2006.06110.x

  47. Cabrita IZ, Mohammed A, Layton M, Ghorashian S, Gilmore A, ChoG, et al. The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. Br J Haematol. 2013 Aug;162(3):400-8. DOI: https://10.1111/bjh.12391

  48. Damy T, Bodez D, Habibi A, Guellich A, Rappeneau S, Inamo J, et al. Haematological determinants of cardiac involvement in adults with sickle cell disease. Eur Heart J. 2016 Apr 7;37(14):1158-67. DOI: https://10.1093/eurheartj/ehv555

  49. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. Eur Respir J. 2012 Jan;39(1):112-8. DOI: https://10.1183/09031936.00134410

  50. Upadhya B, Stacey RB, Ntim W, Knovich MA, Pu M. Echocardiography-derived tricuspid regurgitant jet velocity is an important marker for the progression of sickle-cell disease. Acta Haematol.2014;132(2):152-8 DOI: https://10.1159/000357393

  51. Lobo CL, do Nascimento EM, Abelha R, Queiroz AM, Connes P, Cardoso GP, et al. Risk factors of pulmonary hypertension in Brazilian patients with sickle cell anemia. PLoS One. 2015 Sep 3;10(9):e0137539. DOI: https://10.1371/journal.pone.0137539

  52. Caughey MC, Poole C, Ataga KI, Hinderliter AL. Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review. Br J Haematol. 2015 Aug;170(3):416-24 DOI: https://10.1111/bjh.13447

  53. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011 Jul 7;365(1):44-53. DOI: https://10.1056/NEJMoa1005565

  54. Willen SM, Gladwin MT. What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease? Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):431-4. DOI: https://10.1182/asheducation-2017.1.432

  55. Liem RI, Lanzkron S, Coates TD, de Castro L, Desai AA, Ataga KI, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019 Dec 10;3(23):3867-97. DOI: https://10.1182/bloodadvances.2019000916

  56. Mehari A, Thomas AV, Thomas AN, Johnson MS. Hemodynamic characteristics and outcomes of sickle cell disease associated pulmonary hypertension. Ethn Dis. 2016 Oct 20;26(4):545-52 DOI: https://10.18865/ed.26.4.545

  57. Álvarez O, Wietstruck MA. Sickle cell disease. En: Bertrand P, Sánchez I, eds. Pediatric respiratory diseases. Switzerland: Springer Nature; 2020. p. 529-41. DOI: https://doi.org/10.1007/978-3-030-26961-6_52

  58. Arigliani M, Gupta A. Management of chronic respiratory complications in children and adolescents with sickle cell disease. Eur Respir Rev. 2020 Aug 18;29(157):200054. DOI: https://10.1183/16000617.0054-2020

  59. Newaskar M, Hardy KA, Morris CR. Asthma in sickle cell disease. ScientificWorldJournal. 2011 May 26;11:1138-52 DOI: https://10.1100/tsw.2011.105

  60. Gutiérrez Díaz AI, Arencibia Núñez A, Ramón Rodríguez LG, Svarch E, Jaime Fagundo JC, Machín García S. La drepanocitosis y el asma bronquial. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2013 [acceso 02/05/2021];29(3):[aprox. 0 p.]. Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/57

  61. Pahl K, Mullen CA. Acute chest syndrome in sickle cell disease: Effect of genotype and asthma. Exp Biol Med (Maywood). 2016 Apr;241(7):745-58. DOI: https://10.1177/1535370216636720

  62. Lunt A, Mortimer L, Rees D, Height S, Thein SL, Greenough A. Heterogeneity of respiratory disease in children and young adults with sickle cell disease. Thorax. 2018 Jun;73(6):575-577. DOI: https://10.1136/thoraxjnl-2017-210206

  63. Lunt A, Desai SR, Wells AU, Hansell DM, Mushemi S, Melikian N, et al. Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease. Thorax. 2014 Aug;69(8):746-51 DOI: https://10.1136/thoraxjnl-2013-204809

  64. Cohen RT, Strunk RC, Rodeghier M, Rosen CL, Kirkham FJ, Kirkby J, et al. Pattern of lung function is not associated with prior or future morbidity in children with sickle cell anemia. Ann Am Thorac Soc. 2016 Aug;13(8):1314-23. DOI: https://10.1513/AnnalsATS.201510-706OC

  65. Peña-Batista A, Sierra-Martínez D, Fernández-Águila J, Cabrera-Zamora M, Pino-Blanco R, Fernández-Villares F. Alteraciones funcionales ventilatorias en pacientes adultos con drepanocitosis. Medisur [revista en Internet]. 2020[acceso 02/05/2021];18(1):[aprox. 7 p.]. Disponible en: Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/4391 .

  66. Mesa-Cuervo JR, Cháguez-Leyva O, Hechavarría-Miyares J, Plasencia-Ternblóm A, Losada-Buchillón R, Rodríguez LR, et al. Modificaciones funcionales ventilatorias en pacientes con anemia drepanocítica y antecedentes de síndrome torácico agudo. Rev Cubana Hematol Inmunol Hemoter. 2002[acceso 02/05/2021];18(2):[aprox. 9 p].Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892002000200007 .

  67. Concepción-García CE, Nieves-Paulino R, Camilo-Pantaleón R, Darío- Pimentel R. Función pulmonar en falcémicos homocigotos de 5 a 15 años en consulta de hematología, Hospital Materno Infantil San Lorenzo de los Mina. Agosto-octubre, 2015. Ciencia y Salud 2018; 2(1):49-55.

  68. Lunt A, McGhee E, Sylvester K, Rafferty G, Dick M, Rees D, et al. Longitudinal assessment of lung function in children with sickle cell disease. Pediatr Pulmonol. 2016 Jul;51(7):717-23. DOI: https://10.1002/ppul.23367

  69. Kassim AA, Payne AB, Rodeghier M, Macklin EA, Strunk RC, DeBaun MR. Low forced expiratory volume is associated with earlier death in sickle cell anemia. Blood. 2015 Sep 24;126(13):1544-50. DOI: https://10.1182/blood-2015-05-644435

  70. Rosen CL, Debaun MR, Strunk RC, Redline S, Seicean S, Cravenet DI, et al. Obstructive sleep apnea and sickle cell anemia. Pediatrics. 2014 Aug;134(2):273-81. DOI: https://10.1542/peds.2013-4223

  71. Halphen I, Elie C, Brousse V, Bourgeois ML, Allali S, Bonnet D, et al. Severe nocturnal and postexercise hypoxia in children and adolescents with sickle cell disease. PLoS One. 2014 May 30;9(5):e97462. DOI: https://10.1371/journal.pone.0097462

  72. Wallen GR, Minniti CP, Krumlauf M, EckesI,Allen D, Oguhebe A, et al. Sleep disturbance, depression and pain in adults with sickle cell disease. BMC Psychiatry. 2014 Jul 21;14:207. DOI: https://10.1186/1471-244X-14-207

  73. Sharma S, Efird JT, Knupp C, Kadali R, Liles D, Shiue K, et al. Sleep disorders in adult sickle cell patients. J Clin Sleep Med. 2015 Mar 15;11(3):219-23. DOI: https://10.5664/jcsm.4530

  74. Worsham CM, Martin ST, Nouraie SM, Cohen RT, Klings ES. Clinical and laboratory findings associated with sleep disordered breathing in sickle cell disease. Am J Hematol. 2017 Dec;92(12):E649-51. DOI: https://10.1002/ajh.24892

  75. Sickle Cell Society, Public Health England. Sickle Cell Disease in Childhood: Standards and Recommendations for Clinical Care. 3rd Ed. London, Sickle Cell Society, 2019.

  76. Willen SM, Thornburg CD, Lantos PM. The traveler with sickle cell disease. J Travel Med. Sep-Oct 2014;21(5):332-9 DOI: https://10.1111/jtm.12142

  77. Willen SM, Rodeghier M, Rosen CL, DeBaun MR. Sleep disordered breathing does not predict acute severe pain episodes in children with sickle cell anemia. Am J Hematol. 2018 Aug;93(4):478-85. DOI: https://10.1002/ajh.25013

  78. Willen SM, Rodeghier M, Strunk RC, Rosen CL, Kirkham FJ, Field JJ, et al. Airway hyperresponsiveness does not predict morbidity in children with sickle cell anemia. Am J Respir Crit Care Med. 2017 Jun 1;195(11):1533-1534. DOI: https://10.1164/rccm.201610-1970LE

  79. Dlamini N, Saunders DE, Bynevelt M, Trompeter S, Cox TC, Bucks RS, et al. Nocturnal oxyhemoglobin desaturation and arteriopathy in a pediatric sickle cell disease cohort. Neurology. 2017 Dec 12;89(24):2406-12. DOI: https://10.1212/WNL.0000000000004728

  80. Rotz SJ, Ann O’riordan M, Kim C, Langer N, Cruz C, Schilz R, et al. Nocturnal hemoglobin desaturation is associated with reticulocytosis in adults with sickle cell disease and is independent of obstructive sleep apnea. Am J Hematol. 2016 Sep;91(9):E355-6. DOI: https://10.1002/ajh.24432

  81. Roizenblatt M, Figueiredo MS, Cancado RD, Pollack-Filho F, Arruda MM, Vicari P, et al. Priapism is associated with sleep hypoxemia in sickle cell disease. J Urol. 2012 Oct;188(4):1245-51. DOI: https://10.1016/j.juro.2012.06.015

  82. Kaditis AG, Alonso Alvarez ML, Boudewyns A, Alexopoulos EL, Ersu R, Joosten K, et al. Obstructive sleep disordered breathing in 2- to 18-year-old children: diagnosis and management. Eur Respir J. 2016 Jan;47(1):69-94. DOI: https://10.1183/13993003.00385-2015

  83. Grady AJ, Hankins JS, Haberman B, Schoumacher R, Stocks RM. Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. Sleep Breath. 2017 Sep;21(3):697-701. DOI: https://10.1007/s11325-017-1458-9

  84. vanGeyzel L, Arigliani M, Inusa B, Singh B, Kozlowska W, Chakravorty S, et al. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. Arch Dis Child. 2020 Jun;105(6):575-9. DOI: https://10.1136/archdischild-2019-317862

  85. Qureshi A, Kaya B, Pancham S, Keenan R, Anderson J, AkanniM, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease. Br J Haematol. 2018 May;181(4):460-75. DOI: https://10.1111/bjh.15235

  86. Narang I, Kadmon G, Lai D, Dhanju S, Kirby-Allen M, Odame I, et al. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy. Ann Am Thorac Soc. 2015 Jul;12(7):1044-9. DOI: https://10.1513/AnnalsATS.201410-473OC

  87. Hayes D, Wilson KC, Krivchenia K, Hawkins SM, Balfour-Lynn IM, Gozal D, et al. Home oxygen therapy for children. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 Feb 1;199(3):e5-e23. DOI: https://10.1164/rccm.201812-2276ST

  88. Ip H, Kesse-Adu R, Howard J, Hart N, et al. Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease. Br J Haematol. 2013 May;161(3):455-6. DOI: https://10.1111/bjh.12254

  89. Farrell AN, Goudy SL, Yee ME, Leu RM, Landry AM. Adenotonsillectomy in children with sickle cell disease and obstructive sleep apnea. Int J Pediatr Otorhinolaryngol. 2018 Aug;111:158-61. DOI: https://10.1016/j.ijporl.2018.05.034




2020     |     www.medigraphic.com